| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
-SEC Filing
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development...
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20...